209286-78-2

Basic information

• Product Name: 1-(Phenylsulfonyl)-4-chloro-5-azaindole
• Synonyms: 1-(Phenylsulfonyl)-4-chloro-5-azaindole
• CAS NO: 209286-78-2
• Molecular Formula: C13H9ClN2O2S
• Molecular Weight: 292.74076
• Mol File: 209286-78-2.mol

Chemical Properties

• Boiling Point: 510.0±53.0 °C(Predicted)
• Appearance: /
• Density: 1.45±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.98±0.30(Predicted)
• CAS DataBase Reference: 1-(Phenylsulfonyl)-4-chloro-5-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Phenylsulfonyl)-4-chloro-5-azaindole(209286-78-2)
• EPA Substance Registry System: 1-(Phenylsulfonyl)-4-chloro-5-azaindole(209286-78-2)

Safety Data

• Hazardous Substances Data: 209286-78-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
1-(Phenylsulfonyl)-4-chloro-5-azaindole is used as a key intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Applications:
In the agrochemical industry, 1-(Phenylsulfonyl)-4-chloro-5-azaindole is used as a building block for the creation of novel agrochemicals for [application reason]. Its sulfonyl and chloro substituents contribute to the compound's effectiveness in crop protection and pest control.
Used in Medicinal Chemistry Research:
1-(Phenylsulfonyl)-4-chloro-5-azaindole serves as a valuable research tool in medicinal chemistry for [application reason]. Its unique structural features make it a promising candidate for the study of new drug mechanisms and the development of targeted therapies.
Used in Crop Protection Research:
1-(Phenylsulfonyl)-4-chloro-5-azaindole is also utilized in crop protection research as a potential active ingredient for [application reason]. Its properties may contribute to the development of innovative solutions for enhancing crop yield and resistance against pests and diseases.

Upstream product

• 109113-39-5 1-Benzenesulfonyl-1H-pyrrolo<3,2-c>pyridine 
• 271-34-1 5-azaindole 
• 98-09-9 benzenesulfonyl chloride 
• 60290-21-3 4-chloro-1H-pyrrolo-[3,2-c]-pyridine 

Relevant articles and documents

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.